Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Zhou, Zhen ^a   Chen, Zhi Wei ^a   Yang, Xiao Hua ^a   Shen, Lan ^a   Ai, Xing Hao ^a   Lu, Shun ^a   Luo, Qing Quan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Biomarker; Bone metastasis; Lung cancer

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 4; BONE SIALOPROTEIN; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPONTIN; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR MODEL; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE SRC; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; VISCERAL METASTASIS;

ADULT; AGED; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862225345     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-34     Document Type: Article

References (21)

1. Clinical features of metastatic bone disease and risk of skeletal morbidity. Coleman RE, Clin Cancer Res 2006 12 6243s 6249s 10.1158/1078-0432. CCR-06-0931 17062708 (Pubitemid 44703797)
2. Bone metastasis: pathogenesis and therapeutic implications. Clezardin P, Teti A, et al. Clin Exp Metastasis 2007 24 599 608 10.1007/s10585-007-9112-8 18008175 (Pubitemid 50003596)
3. Mechanisms of breast cancer bone metastasis. Zhang Y, Ma B, Fan Q, Cancer Let 2010 292 1 7 10.1016/j.canlet.2009.11.003
4. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. Wang H, Pan K, Zhang HK, et al. J Cancer Res Clin Oncol 2008 134 535 541 10.1007/s00432-007-0316-8 17917742 (Pubitemid 351422607)
5. Osteopontin increases lung cancer cells migration via activation of the v3 integrin/FAK/Akt and NF-B-dependent pathway. Fong YC, Liu SC, Huang CY, et al. Lung Cancer 2009 64 263 270 10.1016/j.lungcan.2008.09.003 18996613
6. Role of osteopontin in cellular signaling and metastatic phenotype. El-Tanani MK, Front Biosci 2008 13 4276 84 18508510 (Pubitemid 351599683)
7. Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proIiferation. Wai PY, Guo L, Gao C, et al. Surgery 2006 140 132 140 10.1016/j.surg.2006.02.005 16904962 (Pubitemid 44176055)
8. A multigenic program mediating breast cancer metastasis to bone. Kang Y, Siegel PM, Shu W, et al. Cancer Cell 2003 3 537 549 10.1016/S1535-6108(03)00132- 6 12842083 (Pubitemid 36808649)
9. The role of sialoprotein in recognition of bone surface by osteoblasts via integrin. Uemura T, Liu YK, Feng Y, et al. Mat Sci Eng 1997 4 303 10.1016/S0928-4931(97)00015-5
10. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Bellancene A, MerVille MP, Castronovo V, Cancer Res l994 54 2823
11. Interactions between the bone metrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. Fp R, Chappel J, Alvarez JI, et al. J Biol Chem 1993 268 9901 9907 8486670 (Pubitemid 23146055)
12. Increased Expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. Waltregny D, Bellahcene A, de Leval X, et al. J Bone Miner Res 2000 15 834 843 10804012 (Pubitemid 30233406)
13. c-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Myoui A, Nishimura R, Williams PJ, et al. Cancer Res 2003 63 5028 5033 12941830 (Pubitemid 37022641)
14. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? Alarmo EL, Kallioniemi A, Endocr Relat Cancer 2010 17 123 R139 10.1677/ERC-09-0273 20335308
15. Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Ketolainen JM, Alarmo EL, Tuominen VJ, et al. Breast Cancer Res Treat 2010 124 377 386 10.1007/s10549-010-0808-0 20182795
16. Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immuohistochemical study. Spanjol J, Djordjeric G, Markic D, et al. Coll Antropol 2010 34 Suppl 2 119 125 21302710
17. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Hjertner O, Hjrth-Hansen H, Borset M, et al. Blood 2001 7 516 522 (Pubitemid 32060339)
18. Midregion PTHrP and human breast cancer cells. Luparello C, Sci World J 2010 1 1016 1028
19. Parathyroid hormone related protein localization in breast cancers predict improved prognosis. Henderson MA, Danks JA, Slavin JL, et al. Cancer Res 2006 66 2250 2256 10.1158/0008-5472.CAN-05-2814 16489028
20. Crosstalk between cancer cell and bone microenviroment in bone metastasis. Yoneda T, Hiraga T, Biochem Biophys Res Commun 2005 328 679 687 10.1016/j.bbrc.2004.11.070 15694401 (Pubitemid 40208305)
21. Mechanism of osteoblastic bone metastasis of prostate cancer. Yonou H, Ogawa Y, Ochiai A, Clin Calcium 2006 16 557 564 16582505